A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) - Trial NCT06307431
Access comprehensive clinical trial information for NCT06307431 through Pure Global AI's free database. This Phase 2 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 272 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Sharp & Dohme LLC
Timeline & Enrollment
Phase 2
Apr 10, 2024
Jun 08, 2032
Primary Outcome
Disease-Free Survival (DFS)
Summary
The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus
 pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
 The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus
 pembrolizumab with respect to DFS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06307431
Non-Device Trial